antibody-based NK cell stimulant cancer therapeutics
/ Affimed, Roche
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
April 15, 2021
Affimed Reports 2020 Financial Results and Highlights Recent Operational Progress
(GlobeNewswire)
- “AFM24 (EGFR/CD16A)…Affimed expects to provide an update on the dose escalation and initiate the dose expansion cohorts during 2021…Affimed expects to initiate the study in the second half of 2021…AFM28 progressed further in IND-enabling studies and Affimed expects an IND application will be filed in the first half of 2022.”
IND • New trial • Trial status • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1